Novo Nordisk Unveils Phase 3 ESSENCE Subgroup Data in MASH at EASL 2026

At the European Association for the Study of the Liver (EASL) Congress 2026 in May, Novo Nordisk presented new clinical and real-world evidence analyses from its Phase 3 ESSENCE trial program. The presentations evaluated semaglutide 2.4 mg (Wegovy) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, reinforcing the therapeutic potential of GLP-1 receptor agonists in chronic liver disease.

New Subgroup Efficacy and Hepatic Safety Data

The Phase 3 ESSENCE trial is a pivotal program evaluating the safety and efficacy of high-dose semaglutide in treating MASH, a progressive, inflammatory form of liver disease that affects an estimated 250 million people worldwide and often leads to cirrhosis or liver failure.

The new data presented at EASL 2026 focused on underrepresented and high-risk patient populations:

"The data presentations expand upon findings from the company’s Phase 3 ESSENCE trial program evaluating semaglutide 2.4 mg in patients with MASH and liver fibrosis. According to Novo Nordisk, the new analyses focused on hepatic safety, menopausal women, and Japanese patient populations—groups often underrepresented in liver disease research."

Key takeaways from the EASL presentations include:

• Favorable Hepatic Safety: The primary analysis demonstrated a robust liver safety profile for semaglutide across multiple patient subgroups. This is a critical finding because MASH patients typically suffer from severely compromised hepatic function and multiple metabolic comorbidities, making drug safety a paramount concern.
• Menopausal Women Subgroup: Hormonal shifts during menopause are known to accelerate liver fibrosis and exacerbate metabolic dysfunction. The ESSENCE subgroup analysis demonstrated that semaglutide effectively countered these risks, offering a targeted therapeutic option.
• Japanese Patient Subgroup: Asian populations often develop metabolic liver disease at much lower body mass index (BMI) thresholds and with distinct metabolic profiles. The Japanese subgroup analysis confirmed that semaglutide's efficacy and safety remained consistent under these distinct risk parameters.

Addressing a Massive Diagnostic Gap

In addition to clinical trial data, Novo Nordisk presented real-world evidence highlighting the vast commercial runway for MASH treatments. Due to the asymptomatic, "silent" nature of early-stage liver disease, the vast majority of cases remain completely undetected:

"Novo Nordisk also highlighted real-world evidence presented at EASL suggesting that MASH remains substantially underdiagnosed globally, with approximately 90% of cases estimated to be unidentified."

Strategic Takeaways for Investors

Wegovy received conditional FDA approval for MASH in August 2025. The new Phase 3 ESSENCE data presented at EASL 2026 significantly strengthens Novo Nordisk's clinical case, supporting broader global regulatory approvals and insurance coverage. By expanding Wegovy's indications from obesity and cardiovascular risk reduction to chronic liver disease, Novo Nordisk is broadening the clinical utility of semaglutide, helping to defend its market share against next-generation multi-agonists like Eli Lilly's tirzepatide and retatrutide.